MRS allows non-invasive follow-up of treated glioblastomas tumors. There is a large variability, but repetition and modelisation of spectroscopic measurements during longitudinal follow-up could allow us to diminish it and to improve prognostic evaluation especially in long survivors and patients with proliferation relapses. Studying the relationship between MRS measures, segmentation and perfusion parameters could lead to better understanding of tumoral processes and of therapeutic response, especially with regard to chemotherapy, radiotherapy and antiangiogenic molecules and in the future oxidative stress and hypoxia modulators.
This abstract and the presentation materials are available to members only; a login is required.